Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development

9 Meters Biopharma Inc
Bain Biotech ApS
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
Sosei Heptares
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GLP2R for Intestil Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-7570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2020: Hanmi Pharm’s short-bowel syndrome drug wins FDA’s rare pediatric disease status
Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland
Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
May 03, 2019: Hanmi’s short bowel syndrome treatment becomes orphan drug in US
Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
Jan 16, 2019: Therachon is granted Orphan Drug Desigtion by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
Nov 29, 2018: Therachon is granted Orphan Drug Desigtion in the European Union for apraglutide for the treatment of short bowel syndrome
Nov 13, 2018: U.S. FDA accepts for filing Shire’s supplemental New Drug Application for GATTEX (teduglutide [rD origin]) for children with Short Bowel Syndrome
Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 9 Meters Biopharma Inc, H2 2020
Pipeline by Bainan Biotech ApS, H2 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
Pipeline by Huons Global Co Ltd, H2 2020
Pipeline by OPKO Health Inc, H2 2020
Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
Pipeline by Sosei Heptares, H2 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
Pipeline by VectivBio Holding AG, H2 2020
Pipeline by Zealand Pharma AS, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020